Immorta Bio and Collaborators Publish Blueprint for AI-Driven P4 Precision Medicine in Journal of Translational Medicine
核心洞察
A new peer-reviewed Perspective in the Journal of Translational Medicine outlines a practical framework integrating multi-omics, AI, digital twins, and blockchain to transform P4 Medicine from vision into clinical reality.
The publication presents exploratory metabolomic data from over 2,000 individuals, identifying nine metabolites that consistently change with age as potential dynamic biomarkers for monitoring biological aging.
Immorta Bio (搜索) is applying these technologies to the development of SenoVax™, its first-in-class AI-enabled senolytic peptide immunotherapy platform targeting senescent cells.
A peer-reviewed Perspective article published in the Journal of Translational Medicine proposes a comprehensive architectural framework for transforming Predictive, Preventive, Personalized, and Participatory (P4) Medicine from a decades-old aspirational concept into a clinically deployable reality. The publication, titled "Aspiration to Architecture: Multi-Omics, AI, Digital Twins, and Blockchain for P4 Medicine," was developed through a collaboration between Immorta Bio (搜索), Theriome Inc. (搜索), and the American Board of Precision Medicine (搜索).
Although P4 Medicine has been discussed for nearly two decades, its clinical implementation has remained limited. The authors argue that meaningful translation into practice requires the integration of four complementary technologies working in concert: multi-omics to generate comprehensive biological insights, artificial intelligence to convert complex biological data into actionable clinical decisions, digital twins to model individualized treatment strategies before intervention, and blockchain to enable secure patient ownership and sharing of healthcare data.
"For years, precision medicine has been discussed primarily as a concept rather than a complete clinical system," said Dr. Anil Bajnath, Head of the American Board of Precision Medicine (搜索). "This publication outlines a practical framework for integrating multi-omics, artificial intelligence, digital twins, and secure patient data ownership into a unified model of care."
Proof-of-Concept Metabolomic Data
As a demonstration of the framework's potential, the publication presents exploratory metabolomic data from more than 2,000 individuals, identifying nine metabolites that consistently change with age. These findings illustrate how multi-omics approaches may ultimately provide dynamic biomarkers capable of monitoring biological aging and therapeutic response in real time, offering a window into the kind of molecular profiling that could underpin P4 Medicine.
An Integrated, Continuously Learning Ecosystem
The proposed framework envisions an ecosystem where each technology reinforces the others. Multi-omics generates the raw biological data; AI interprets that data to guide clinical decisions; digital twins allow clinicians to simulate treatment strategies on virtual patient models before real-world intervention; and blockchain ensures that patients retain ownership and control over their health data while enabling secure sharing across the care continuum.
"The future of medicine will not be built around isolated biomarkers or standalone AI models," said Dr. Boris N. Reznik, Chairman and CEO of Immorta Bio (搜索). "Instead, we envision an integrated ecosystem where molecular profiling, artificial intelligence, digital twins, and secure patient-owned data continuously reinforce one another to enable truly predictive, preventive, personalized, and participatory healthcare."
Alignment with Immorta Bio (搜索)'s Therapeutic Pipeline
The concepts described in the publication closely align with Immorta Bio (搜索)'s long-term strategy. The company is integrating artificial intelligence, computational biology, and multi-omics into the development of SenoVax™, its first-in-class senolytic peptide immunotherapy platform designed to selectively eliminate senescent cells. Immorta Bio's pipeline also includes StemCellRevivify™, a regenerative cell therapy platform aimed at restoring youthful regenerative capacity. Together, these platforms target the two principal biological drivers of aging while creating therapeutic opportunities across oncology, organ failure, sepsis, and other age-related diseases.
"The technologies described in this Perspective closely align with the direction we are taking at Immorta Bio (搜索)," said Dr. Thomas E. Ichim, President and Chief Scientific Officer of Immorta Bio and co-author of the publication. "We are integrating artificial intelligence, computational biology, and multi-omics into the development of SenoVax™, our first-in-class senolytic peptide immunotherapy platform. We believe these technologies can significantly accelerate therapeutic development while enabling more precise immunotherapy design."
Collaborative Expertise
The publication highlights the complementary strengths of the three collaborating organizations: Theriome's expertise in large-scale multi-omics and systems biology, the American Board of Precision Medicine (搜索)'s leadership in advancing precision healthcare through physician training and certification, and Immorta Bio (搜索)'s focus on translating advances in aging biology into innovative therapeutics. Theriome, based in Phoenix, Arizona, anchors each pillar of P4 Medicine to a specific technology, offering wellness tests such as Aristotle+, which measures metabolites from a finger-prick dried blood spot, and Élie, which reads the gut microbiome from an at-home stool sample.